Treatment of Acitrom-Induced INR of 6.5
For an asymptomatic patient with acitrom-induced INR of 6.5, administer 2 mg of oral vitamin K and withhold the anticoagulant temporarily, with close INR monitoring. 1
Management Algorithm
Immediate Assessment
First, determine if the patient has any bleeding:
- No bleeding (asymptomatic overdose): Follow conservative management below
- Active bleeding: Requires aggressive reversal with prothrombin complex concentrate (PCC)
For Asymptomatic INR 6.5 (No Bleeding)
The 2025 French guidelines provide the most recent and specific guidance for this exact scenario 1:
Treatment approach:
- Administer 2 mg oral vitamin K (for target INR of 2.5, when measured INR is 6-10)
- Withhold acitrom temporarily until INR returns to therapeutic range
- Do NOT administer PCC or plasma - this is specifically not recommended for asymptomatic overdose 1
- Monitor INR closely - recheck within 24-48 hours
If Active Bleeding is Present
Should bleeding develop, the approach changes dramatically 2:
For major bleeding with INR >6:
- Administer 4-factor PCC at 50 units/kg 2
- Plus intravenous vitamin K 10 mg (always give vitamin K with PCC)
- For intracranial hemorrhage: Consider fixed-dose PCC 1500 units 2
Outpatient vs. Inpatient Management
The patient may be managed as an outpatient if ALL of the following are met 1:
- Satisfactory understanding or caregiver present at home
- No high short-term bleeding risk factors:
- Platelet count >50 G/L
- Not on multiple antithrombotic agents (aspirin alone is acceptable)
- No recent bleeding or stroke (<1 month)
- No progressive lesion with hemorrhagic potential
- Ability to arrange INR monitoring and clinical follow-up
- Etiological investigation planned
Critical Pitfalls and Caveats
The Phenprocoumon/Long-Acting VKA Problem
Acitrom (acenocoumarol) has a shorter half-life than phenprocoumon, but INR rebound remains a concern. Recent evidence shows that after reversal of VKAs with INR ≥6, there is significant risk of supratherapeutic INR recurrence 3. Monitor INR at 24 hours, 48 hours, and potentially up to 14 days post-reversal, as the anticoagulant effect can return.
Avoid Over-Reversal
Do not use PCC or fresh frozen plasma for asymptomatic elevated INR - this is explicitly not recommended and increases thrombotic risk without improving outcomes 1. The 2025 guidelines specifically state this with Grade 2 evidence.
Vitamin K Dosing Precision
The dose matters: 2 mg oral vitamin K for INR 6-10 with target INR 2.5 1. Higher doses (5 mg) are reserved for INR >10. Oral administration is preferred over IV for asymptomatic cases, as it provides more gradual correction and lower risk of over-correction.
Investigation Required
Always investigate the cause of INR elevation:
- Medication interactions (antibiotics, antifungals, NSAIDs)
- Dietary changes (reduced vitamin K intake)
- Acute illness affecting liver function
- Dosing errors or compliance issues
When to Resume Anticoagulation
Once INR normalizes and the precipitating factor is addressed, restart acitrom at a reduced dose (typically 10-20% reduction from previous maintenance dose). The indication for anticoagulation still exists, so prolonged discontinuation increases thrombotic risk.